After One Dose of Gene Therapy Hemophilia B Patients Maintain Near-normal Levels of Clotting Factor
At ASH, CHOP Hematologist Leads Clinical Trial in Which All Subjects Safely Maintain Factor IX Expression That Curtails Disabling Bleeding
Published on in CHOP News , International Update